Work Package 4

Validation of immune markers associated to CMV infection, associated to poor outcomes during CMV infection and associated to long-term outcomes

Lead partner
Institut Catala de la Salut | Vall d’Hebron University Hospital

Task leaders and participating partners

WP Objectives

The goal is to reproduce and generalise global signature found in WP2 and WP3, helping physician to

  • Personalise the management of CMV prevention: avoid either preemptive strategy and antiviral preventive strategy, identify patients who will benefit from new mode of prevention such as mTORi

  • Personalise the management of CMV curative treatment: adapt the duration of CMV treatment, identify patients who will benefit from immunosuppressive drug modulation such as mTORi or from immunotherapy.

  • Analyse this signature together with clinical feature to predict long-term outcomes